Department of Immunology and Serology, Faculty of Pharmaceutical Sciences in Sosnowiec, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, 40‑055 Katowice, Poland.
Department of Molecular Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, 40‑055 Katowice, Poland.
Mol Med Rep. 2022 Oct;26(4). doi: 10.3892/mmr.2022.12812. Epub 2022 Aug 3.
Understanding the relationship between the coexistence of inflammatory and neoplastic processes in ovarian cancer, particularly those involving chemokines and their receptors, may help to elucidate the involvement of the studied parameters in tumor pathogenesis and could lead to improved clinical applications. Therefore, the present study aimed to analyze the levels of C‑X‑C motif chemokine ligand 8 (CXCL8), and its receptors C‑X‑C chemokine receptor (CXCR)1 and CXCR2, in the serum and peritoneal fluid of women with ovarian cancer, and to evaluate the association between the expression of these parameters in tumor tissue and patient characteristics, particularly the degree of histological differentiation. The study group included women with ovarian cancer diagnosed with serous cystadenocarcinoma International Federation of Gynecology and Obstetrics stage IIIc and a control group, which consisted of women who were diagnosed with a benign lesion (serous cystadenoma). The transcript levels of , and were evaluated using reverse transcription‑quantitative PCR (RT‑qPCR). The quantitative analysis was carried out using the LightCycler® 480 System and GoTaq® 1‑Step RT‑qPCR System, according to the manufacturers' instructions. The concentration of CXCL8 in serum and peritoneal fluid was determined using a Human Interleukin‑8 ELISA kit, and the concentrations of CXCR1 and CXCR2 were determined using the CLOUD‑CLONE ELISA kit. Local and systemic disturbances in immune and inflammatory responses involving the CXCL8 chemokine and its receptors indicated the involvement of these studied parameters in the pathogenesis of ovarian cancer. Immunoregulation of the CXCL8‑CXCR1 system may influence the course of the inflammatory process accompanying ovarian cancer development, which may result in the identification of novel clinical applications; however, further studies are required.
了解卵巢癌中炎症和肿瘤过程共存的关系，特别是涉及趋化因子及其受体的关系，可能有助于阐明所研究参数在肿瘤发病机制中的作用，并可能导致临床应用的改善。因此，本研究旨在分析卵巢癌患者血清和腹腔液中 C‑X‑C 基序趋化因子配体 8（CXCL8）及其受体 C‑X‑C 趋化因子受体（CXCR）1 和 CXCR2 的水平，并评估这些参数在肿瘤组织中的表达与患者特征之间的关系，特别是组织学分化程度的关系。研究组包括诊断为国际妇产科联合会（FIGO）IIIc 期浆液性囊腺癌的卵巢癌患者，对照组为诊断为良性病变（浆液性囊腺瘤）的患者。采用逆转录定量 PCR（RT‑qPCR）评估 、 和 的转录水平。根据制造商的说明，使用 LightCycler®480 系统和 GoTaq®1‑Step RT‑qPCR 系统进行定量分析。使用人白细胞介素 8 ELISA 试剂盒测定血清和腹腔液中 CXCL8 的浓度，使用 CLOUD‑CLONE ELISA 试剂盒测定 CXCR1 和 CXCR2 的浓度。CXCL8 趋化因子及其受体的局部和全身免疫和炎症反应紊乱表明这些研究参数参与了卵巢癌的发病机制。CXCL8‑CXCR1 系统的免疫调节可能影响伴随卵巢癌发展的炎症过程的进程，这可能导致新的临床应用的确定；然而，还需要进一步的研究。
